Morrison Briggs insider trades
Morrison Briggs has filed 38 Form 4s with the SEC that we hold, for Syndax Pharmaceuticals Inc (SNDX) (Director), Arvinas, INC. (ARVN) (Director), Werewolf Therapeutics, Inc. (HOWL) (Director) and CARM (Director), among 6 companies in all. Across all of them we count 2 purchases worth $495.1K and 29 sales worth $26.4M reported on Form 4. In the last 12 months: 1 purchase ($268.0K) and 0 sales ($0). The largest single trade was a sale of 114,339 shares of Syndax Pharmaceuticals Inc worth $2.6M, dated 2022-09-19. The first filing on our record is dated 2021-09-21 and the latest 2026-06-26.
Syndax Pharmaceuticals Inc (SNDX)
| Trade date | Code | Shares | Value as filed | Filed |
|---|---|---|---|---|
| 2021-09-17 | S, sale reported on Form 4 | 70,262 | $1.4M | 2021-09-21 |
| 2021-09-20 | S, sale reported on Form 4 | 50 | $1.0K | 2021-09-21 |
| 2021-12-17 | S, sale reported on Form 4 | 35,156 | $703.1K | 2021-12-20 |
| 2022-04-01 | S, sale reported on Form 4 | 70,545 | $1.2M | 2022-04-05 |
| 2022-04-01 | S, sale reported on Form 4 | 24,500 | $427.3K | 2022-04-05 |
| 2022-04-01 | S, sale reported on Form 4 | 6,000 | $104.6K | 2022-04-05 |
| 2022-04-04 | S, sale reported on Form 4 | 3,128 | $57.2K | 2022-04-05 |
| 2022-07-01 | S, sale reported on Form 4 | 62,292 | $1.2M | 2022-07-05 |
| 2022-09-14 | S, sale reported on Form 4 | 87,645 | $2.1M | 2022-09-16 |
| 2022-09-15 | S, sale reported on Form 4 | 66,775 | $1.6M | 2022-09-16 |
| 2022-09-16 | S, sale reported on Form 4 | 53,034 | $1.2M | 2022-09-16 |
| 2022-09-16 | S, sale reported on Form 4 | 71,966 | $1.7M | 2022-09-16 |
| 2022-09-19 | S, sale reported on Form 4 | 114,339 | $2.6M | 2022-09-21 |
| 2022-09-20 | S, sale reported on Form 4 | 59,649 | $1.4M | 2022-09-21 |
| 2023-02-06 | S, sale reported on Form 4 | 52,854 | $1.4M | 2023-02-08 |
| 2023-03-13 | S, sale reported on Form 4 | 52,854 | $1.2M | 2023-03-14 |
| 2023-04-10 | S, sale reported on Form 4 | 52,855 | $1.0M | 2023-04-12 |
| 2023-05-09 | S, sale reported on Form 4 | 52,855 | $1.1M | 2023-05-10 |
| 2023-06-09 | S, sale reported on Form 4 | 28,273 | $598.8K | 2023-06-09 |
| 2023-06-09 | S, sale reported on Form 4 | 24,582 | $520.6K | 2023-06-09 |
| 2023-07-10 | S, sale reported on Form 4 | 52,855 | $1.1M | 2023-07-11 |
| 2023-08-09 | S, sale reported on Form 4 | 52,855 | $965.7K | 2023-08-10 |
Arvinas, INC. (ARVN)
| Trade date | Code | Shares | Value as filed | Filed |
|---|---|---|---|---|
| 2022-01-14 | S, sale reported on Form 4 | 3,833 | $250.1K | 2022-01-19 |
| 2022-01-14 | S, sale reported on Form 4 | 2,108 | $142.7K | 2022-01-19 |
| 2022-01-14 | S, sale reported on Form 4 | 9,919 | $638.1K | 2022-01-19 |
| 2022-01-14 | S, sale reported on Form 4 | 5,100 | $343.1K | 2022-01-19 |
| 2022-04-14 | S, sale reported on Form 4 | 3,102 | $202.4K | 2022-04-18 |
| 2022-04-14 | S, sale reported on Form 4 | 7,104 | $469.4K | 2022-04-18 |
| 2022-04-14 | S, sale reported on Form 4 | 10,754 | $720.8K | 2022-04-18 |
| 2025-09-22 | P, purchase reported on Form 4 | 30,000 | $227.1K | 2025-09-24 |
| 2026-03-06 | P, purchase reported on Form 4 | 20,000 | $268.0K | 2026-03-09 |
Werewolf Therapeutics, Inc. (HOWL)
No purchase or sale of common stock reported here; these filings cover grants, option exercises or other codes.
CARM
No purchase or sale of common stock reported here; these filings cover grants, option exercises or other codes.
RPTX
No purchase or sale of common stock reported here; these filings cover grants, option exercises or other codes.
CRISPR Therapeutics AG (CRSP)
No purchase or sale of common stock reported here; these filings cover grants, option exercises or other codes.
Counted from the Form 4 filings this reporting owner (SEC CIK 1654430) filed on EDGAR. Values are the transaction values as filed. See every filing on EDGAR, or browse insider buying and today's insider purchases.
Source: U.S. Securities and Exchange Commission (EDGAR) and other official
government data · Updated 2026-10-12 ·
For informational purposes only, not investment advice.
Privacy · Terms